Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Virios Therapeutics Inc
(NQ:
VIRI
)
0.2105
+0.0009 (+0.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Virios Therapeutics Inc
< Previous
1
2
Next >
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
April 25, 2023
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia
Via
MarketBeat
Exposures
Product Safety
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
November 29, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
November 03, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics, Inc. Announces Closing of Public Offering
September 22, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics, Inc. Announces Pricing of Public Offering
September 19, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics, Inc. Announces Proposed Public Offering
September 19, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
September 19, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
August 15, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
August 10, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
August 09, 2022
Via
ACN Newswire
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
August 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
August 04, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
July 26, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results
July 19, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia
June 01, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 05, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia
April 28, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 17, 2022
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID
February 28, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
January 26, 2022
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce...
From
RedChip
Via
AccessWire
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference
January 04, 2022
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
December 01, 2021
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 11, 2021
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021
November 04, 2021
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
September 08, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 02, 2021
From
Virios Therapeutics, Inc. (VIRI)
Via
Business Wire
Virios Therapeutics Announces New Social Media Profiles
August 19, 2021
From
Virios Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.